Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | GSK3A | P49840 | 1/20 | 0.30 |
| ▸ | GSK3B | P49841 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21363702 | 0.80 | ADORA2A (0.45) | TRPA1ADORA2AADORA1GSK3AGSK3B | |
| SCHEMBL22477725 | 0.79 | ADORA2A (0.37) | TRPA1ADORA2AADORA1GSK3AGSK3B | |
| SCHEMBL21363374 | 0.78 | TRPA1 (0.37) | TRPA1 | |
| SCHEMBL21363503 | 0.73 | TRPA1 (0.42) | TRPA1ADORA2AADORA1KMT2ARXFP1 | |
| SCHEMBL25100649 | 0.73 | ADORA2A (0.47) | TRPA1ADORA2AADORA1KMT2AGSK3A | |
| SCHEMBL22477724 | 0.70 | TRPA1 (0.46) | TRPA1KMT2A | |
| SCHEMBL21363533 | 0.70 | TRPA1 (0.47) | TRPA1ADORA2AADORA1 | |
| SCHEMBL22210503 | 0.69 | ADORA2A (0.39) | TRPA1ADORA2AADORA1GSK3AGSK3B | |
| SCHEMBL22477709 | 0.68 | TRPA1 (0.35) | TRPA1 | |
| SCHEMBL25165850 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190284179-A1 | OXADIAZOLE TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | GENENTECH, INC. (US) | 2019-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190284179-A1 | OXADIAZOLE TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | TRPA1, TRPV1, TRPV3 | TRPA1 1/4885ADORA2A 209/4885ADORA1 42/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.